Inflammatory bowel diseases patients eligible for biological therapy represent a group with considerable disease burden and biologics only achieve 40% clinical remission rates in responders after 1 year of therapy.
Dual biological therapy with anti-TNF, vedolizumab or ustekinumab in inflammatory bowel disease: a systematic review with pool analysis
Ribaldone, Davide Giuseppe;Pellicano, Rinaldo;Vernero, Marta;Caviglia, Gian Paolo;Saracco, Giorgio Maria;Morino, Mario;
2019-01-01
Abstract
Inflammatory bowel diseases patients eligible for biological therapy represent a group with considerable disease burden and biologics only achieve 40% clinical remission rates in responders after 1 year of therapy.
File in questo prodotto:
| File | Dimensione | Formato | |
|---|---|---|---|
|
systematic review.pdf
Accesso aperto
Tipo di file:
PREPRINT (PRIMA BOZZA)
Dimensione
177.7 kB
Formato
Adobe PDF
|
177.7 kB | Adobe PDF | Visualizza/Apri |
I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.
